Celcuity (CELC) vs IDEAYA Biosciences (IDYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Celcuity (CELC) over the past year, gaining 34.7% versus a gain of 33.4%. Over five years, CELC leads with a +260.8% price change compared with +56.8% for IDYA. IDEAYA Biosciences is the larger company by market cap ($3.50 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | IDYA |
|---|---|---|
| Share price | $65.78 | $36.26 |
| Market cap | $3.22B | $3.50B |
| 1-day change | -7.68% | -1.01% |
| YTD return | -34.16% | +4.89% |
| 1-year return | +33.43% | +34.70% |
| 5-year return | +260.82% | +56.77% |
| EPS (TTM) | $-4.17 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $151.02 | $42.68 |
| 52-week low | $45.03 | $26.05 |
| Distance from 52-week high | -56.44% | -15.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.54% | +45.48% |
| Average volume | 1.19M | 799.78K |
| Shares outstanding | 48.93M | 96.49M |
| Employees | 155 | 145 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
CELC vs IDYA FAQ
Which is bigger, Celcuity or IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.50B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or IDYA?
IDYA returned +34.70% over the past 12 months, compared with +33.43% for CELC (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and IDEAYA Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Celcuity and Biotechnology: Pharmaceutical Preparations for IDEAYA Biosciences.